Navigation Links
Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS
Date:3/20/2013

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. The therapy may not be effective for all patients, but those with trisomy 8 chromosomal disorder have higher rates of stable disease and respond better to treatment with dasatinib, the study shows.

Results of this study appear in the March issue of Leukemia Research.

Myelodysplastic syndromes are disorders of the stem cell in bone marrow. The marrow does not produce enough normal blood cells for the body. As the number of quality blood-forming cells declines, blood production is impaired.

According to the researchers, stem cell transplantation is the only potentially curative option for MDS but also has risks of morbidity and mortality. A class of medication called azanucleosides is the only approved medication for patients with an advanced stage of this disease. The outcome after failure of azanucleosides is poor. Therefore, new therapies for MDS are needed, said the study authors.

Dasatinib, a multikinase inhibitor, has been approved by the Food and Drug Administration for patients with chronic myelogenous leukemia. The drug has promising potential because of its activity against a broad spectrum of tyrosine kinases, which are enzymes that function as an 'on' or 'off' switch for many cellular functions, such as increased activation of cell migration, proliferation, survival, invasion and angiogenesis (tumor blood vessel growth).

"This phase II trial was to assess whether dasatinib would be beneficial for patient with higher risk MDS whose previous treatments had failed," said study corresponding author Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies and member of the Chemic
'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Cancer doesnt change young girls desire to have children, Moffitt Cancer Center study shows
2. Surgery and radiation improve survival for metastatic gastric cancer patients, Moffitt study shows
3. Moffitt researchers say silencing of retinoblastoma gene regulates differentiation of myeloid cells
4. Moffitt researchers find potential new therapeutic target for treating non-small cell lung cancer
5. Moffitt Cancer Center researchers develop automated breast density test linked to cancer risk
6. Tumor cells engineer acidity to drive cell invasion, Moffitt Cancer Center researchers say
7. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
8. Moffitt study shows smoking cessation more successful for cancer patients who quit before surgery
9. Hispanics leery of health care providers, often avoid cancer screenings, Moffitt study shows
10. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
11. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... the launch of a new product suite designed to provide pharmaceutical and healthcare ... trends based on multi-sourced and cross-referenced data from regulatory filings (including the FDA ...
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale Capital ... announced the closing of a $118 million FHA-insured loan modification refinancing for Johnston ... Smithfield and Clayton, North Carolina. JHSC is a joint venture of Johnston ...
(Date:8/4/2015)... ... August 04, 2015 , ... Updated enrollment data on the top U.S. health ... be accessed at http://www.AISHealth.com . The data is free to all registered users ... tables and charts on the website’s “Data” section include:, , ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental ... and crafts, toys, novelties, and school supplies, has developed engaging and affordable teacher ... exclusive collection includes student rewards, classroom decorations, crafts and educational resources featuring ...
(Date:8/4/2015)... ... 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry serving Ohio ... Well videos to preparing high school athletes for fall sports. , In a concise video ... , What steps to take to help prevent injuries , ...
Breaking Medicine News(10 mins):Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 2Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2
... HealthDay Reporter , TUESDAY, Sept. 6 (HealthDay News) ... as ibuprofen during the first stage of their pregnancy ... suggests. "We,re seeing a 2.4-fold increased risk ... pregnancy," said Anick Berard, senior author of a paper ...
... U.S. Food and Drug Administration (FDA) clears the path for ... estimating the risk of ovarian cancer in women with a ... and use of a combination of blood tests for proteins ... (ROMA). Research demonstrates that examining levels of HE4 and CA125 ...
... PARK, Md. - Amid ongoing concerns about E. coli, ... take a unique approach to make imports bound for ... those foods intensive, hands-on lab training in U.S. government ... "The more we can get foreign food facilities ...
... German . The stomach bacterium Helicobacter pylori ... gastric cancer, the third most common cause of cancer-related deaths in ... identified a mechanism of Helicobacter pylori that damages the DNA of ... transformation. Gastric cancer is one of the most common and ...
... cells is an effective treatment for patients with malignant ... cells are crucial to the outcome. Researchers from Lund ... the quality of the transplanted cells using ultrasound for ... blood stem cell transplant is often the only treatment ...
... , This release is available in German . ... they react with a suitable behavioural response and do not ... is the case, for example, with patients who suffer from ... from the Max Planck Institute of Psychiatry have discovered two ...
Cached Medicine News:Health News:NSAIDs May Raise Miscarriage Risk: Study 2Health News:NSAIDs May Raise Miscarriage Risk: Study 3Health News:FDA clears biomarker test for ovarian cancer 2Health News:FDA clears biomarker test for ovarian cancer 3Health News:For safer food imports, Teach foreign lab workers US requirements 2Health News:For safer food imports, Teach foreign lab workers US requirements 3Health News:Stomach bacterium damages human DNA 2Health News:Ultrasound improves stem cell transplants 2Health News:Control of fear in the brain decoded 2Health News:Control of fear in the brain decoded 3
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015  Mirati Therapeutics, ... focusing on genetic and epigenetic drivers of cancer, will be ... August 11, 2015 at 1:55 p.m. ET (10:55 a.m. PT) ... Baum , M.D., Ph.D., president and CEO of Mirati, will ... of the presentation will be accessible on the "Investors" page ...
(Date:8/3/2015)... 2015   The Intellectual Property and Science ... provider of intelligent information for businesses and professionals ... Pharmaceutical R&D Factbook , the biopharmaceutical industry,s leading ... declines in R&D, the analysis identifies a surge ... and forecasts sales to reach $1.3 trillion by ...
Breaking Medicine Technology:Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3Pharma Sales to Grow Beyond $1 Trillion 2
... June 21, 2010 ReportsandReports announces it Will,Carry Cardiovascular Devices Market ... , , ... http://www.reportsandreports.com/market-reports/netherlands-cardiovascular-de ,vices-market-outlook-to-2016/) , , , ... (Due to the length of these URLs, it may be necessary to copy ...
... AHMEDABAD, India , June 21, 2010 ... healthcare companies has,received Phase I clinical trial permission from the DCGI for ... Centre using a,unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule. ... ...
Cached Medicine Technology:Cardiovascular Devices Market Outlook June Update by ReportsandReports 2Cardiovascular Devices Market Outlook June Update by ReportsandReports 3Cardiovascular Devices Market Outlook June Update by ReportsandReports 4Cardiovascular Devices Market Outlook June Update by ReportsandReports 5Cardiovascular Devices Market Outlook June Update by ReportsandReports 6Cardiovascular Devices Market Outlook June Update by ReportsandReports 7Cardiovascular Devices Market Outlook June Update by ReportsandReports 8Cardiovascular Devices Market Outlook June Update by ReportsandReports 9Cardiovascular Devices Market Outlook June Update by ReportsandReports 10Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 2Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 3
... Cost-effective, portable, continuous, or spot ... with alarms and an internal ... and Sleep Study modes make ... the hospital or clinical environment; ...
... The Autocorr Plus, the fourth ... cost-effective, versatile pulse oximeter/ECG/Respiration Monitor, with ... detect/reject, digital oximetry with SAC (Serial ... high-resolution electroluminescent screen display provides two ...
... Management Program is a Windows based, easy-to-use ... Hand-Held Pulse Oximeter. Using the Smiths ... it rapidly downloads information collected during sleep ... and assists in the Clinician's interpretation by ...
The automated and pivoting M2 hand-piece incorporates two powerful, independent electric motors : one controls the blade oscillation at 15,000 RPM and the second controls the high-torque advance of t...
Medicine Products: